New EU Speedy Review Hopefuls: Novimmune, AveXis, bluebird bio, and Loxo Oncology

It is not easy for companies to convince the European Medicines Agency that their marketing applications merit accelerated assessment. Four new hopefuls are about to find out whether they have been successful.

Business time concept as a group of running businessmen and businesswomen using a giant clock to cross over a cliff as a bridge as a metaphor for schedule and appointment speed as a 3D illustration.
The EMA is deciding whether to fast track four products

NovImmune, AveXis, bluebird bio,and Loxo Oncologyare all close to filing for potential approval in the EU investigational therapies that they hope will be fast-tracked through the system.

The products include two gene therapies: onasemnogeneabeparvovec (AveXis, recently acquired by Novartis) and LentiGlobin (bluebird bio). The other two...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards